CA-NEXON-AMERICA-INC
World-renowned MMORPG MapleStory announced today its highly anticipated Explorer Bowman class Pathfinder will be available to players on June 26 , with a pre-creation period starting June 12 . In the game’s update following the conclusion of the Black Mage storyline, players can explore the new Adventure Island events, take on a new theme dungeon, and level up faster with new characters via the Tera Burning Project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005050/en/
Pathfinder pre-creation will start on June 12 and will allow players to choose their Pathfinder’s features such as gender, hair color, and more before rolling out their characters for play on June 26. From June 12 to July 23, players will also enjoy the Tera Burning Project , where one new character per account will gain the extraordinary ability to gain a total of three levels each time they level up!
Starting June 12, players can also participate in a number of engaging events in Adventure Island , including Adventure Bingo, Maplerunner, Reverse Battle, and more. Through these events, players can work on their Adventurer Tier and collect Adventure Coins to purchase new items in the Adventure Coin Shop.
The update also brings massive improvements to gameplay systems to help players of all levels. These improvements include refining tutorial and job advancement quests, improving rewards for low level theme dungeons, increasing meso drops in Reboot worlds, as well as lowering quest requirements for 5th Job advancement and improving Star Force success rates and Arcane Symbol improvement costs. Multiple jobs will also be getting skill revamps in order to improve their abilities as well as increase consistency across the various jobs. The new theme dungeon, Secret Forest of Elodin, will also be available for players level 30 to 59 to explore.
Players who visit the Return to Adventure event now through June 10 can earn the Adventure Microsite Gift Box by clicking on the “Get Gifts Now” button on the page. Those who participate in the Return to Adventure event can also receive additional gift boxes with tons of new and exclusive prizes on June 12.
For more details on the MapleStory Pathfinder update, visit http://bit.ly/bw-maplestory-pathfinder .
Assets :
Social Media:
About MapleStory
With 14 years of sustained gaming excellence, MapleStory remains a critically acclaimed classic MMORPG with millions of registered active players around the world. First released in North America in 2005, MapleStory has experienced memorable in-game events, over 274 million created characters, and still is the World’s Largest Online Adventure. For more information about the game, please visit http://maplestory.nexon.net .
About Nexon America Inc. http://www.nexon.net
Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO) is a global leader in online games with more than 80 live games operated across more than 190 countries. Nexon America introduced micro-transactions and the free-to-play business model in 2005, and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Nexon is listed on the Tokyo Stock Exchange, and the company was placed on the Nikkei Stock Index 300 in 2017.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005050/en/
Contact:
Media Contact Wahid Lodin B/HI for Nexon America wahid_lodin@bhimpact.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom